Fevipiprant

• UNSPSC Description:

  Fevipiprant (QAW039, NVP-QAW039) is s an orally active, selective, reversible prostaglandin D2 (DP2) receptor antagonist with an Kd value of 1.14 nM. Fevipiprant has the potential for the research of bronchial asthma[1][2][3].

• Target Antigen:

  CRTH2 (GPR44); Prostaglandin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Fevipiprant.html

• Solubility:

  DMSO : ≥ 32 mg/mL

• Smiles:

  O=C(O)CC1=C(C)N(CC2=CC=C(S(=O)(C)=O)C=C2C(F)(F)F)C3=NC=CC=C31

• Molecular Weight:

  426.41

• References & Citations:

  [1]Brightling C, et al. The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant. Pulm Pharmacol Ther. 2021 Jun;68:102030.|[2]Lee HY, et al. Blockade of thymic stromal lymphopoietin and CRTH2 attenuates airway inflammation in a murine model of allergic asthma. Korean J Intern Med. 2020 May;35(3):619-629. |[3]Weintraub NL, et al. Role of prostaglandin D2 receptors in the pathogenesis of abdominal aortic aneurysm formation. Clin Sci (Lond). 2022 Mar 18;136(5):309-321.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 3

• CAS Number:

  872365-14-5